Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-07-17 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
SC TO-T/A Filing
Regulatory Filings
2025-07-17 English
Communiqué de presse : Le SAR446597 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de l’atrophie géographique liée à la dégénérescence maculaire liée à l’âge
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing that the FDA has granted 'fast track' designation to one of their pipeline drug candidates (SAR446597). It details the clinical development, the nature of the drug, and the medical condition it targets. As this is a general corporate announcement regarding regulatory progress and R&D updates that does not fit into specific financial reporting categories like earnings, dividends, or governance, it falls under the 'Regulatory Filings' (RNS) category as the standard fallback for corporate news announcements.
2025-07-16 French
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing that the US FDA has granted 'fast track designation' to one of their pipeline gene therapies (SAR446597). It provides details on the drug's mechanism, the clinical condition (geographic atrophy), and future development plans. As this is a general regulatory announcement regarding company operations and product development that does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2025-07-16 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and contains detailed tables listing daily share repurchase transactions by Sanofi. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of companies buying back their own shares.
2025-07-15 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosures of trading in own shares' and provides a detailed table of share repurchase transactions (dates, volumes, and prices) conducted by Sanofi. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS), which covers reports of a company buying back its own shares.
2025-07-15 English
SC TO-T/A Filing
Regulatory Filings
2025-07-10 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.